Rasna Therapeutics Inc
Actavia Life Sciences, Inc., a leukemia-focused biotechnology company, develops therapeutics for the treatment of acute myeloid leukemia (AML) and other forms of leukemia and lymphoma in the United States. It is developing RASP-201, an orally dosed selective reversible inhibitor of lysine specific demethylase (LSD1), which is a pathway that blocks differentiation and confers a poor prognosis to A… Read more
Rasna Therapeutics Inc (RASP) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of March 2024: 0.016x
Based on the latest financial reports, Rasna Therapeutics Inc (RASP) has a cash flow conversion efficiency ratio of 0.016x as of March 2024.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-35.79K) by net assets ($-2.18 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Rasna Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2013–2023)
This chart illustrates how Rasna Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Rasna Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Rasna Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
KOMATSU
MU:KOM1
|
0.049x |
|
TRACTOR SUPPLY (TR4.SG)
STU:TR4
|
0.038x |
|
MKB Nedsense N.V.
LSE:0ML7
|
N/A |
|
ACURX PHARMACEUT. DL-001
F:3ZO
|
N/A |
|
SNEP
BC:SNEP
|
N/A |
|
AdvanceTC Limited
PINK:ATCLF
|
0.000x |
|
Cavalry Capital Corp.
V:CVY-P
|
-0.184x |
|
Rekah Pharmaceutical Industry Ltd
TA:REKA
|
0.026x |
Annual Cash Flow Conversion Efficiency for Rasna Therapeutics Inc (2013–2023)
The table below shows the annual cash flow conversion efficiency of Rasna Therapeutics Inc from 2013 to 2023.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2023-09-30 | $-1.96 Million | $-8.52K | 0.004x | -97.65% |
| 2022-09-30 | $-1.69 Million | $-312.66K | 0.185x | +68.06% |
| 2021-09-30 | $-2.66 Million | $-293.39K | 0.110x | +17.25% |
| 2020-09-30 | $-2.67 Million | $-251.33K | 0.094x | +357.41% |
| 2019-09-30 | $2.54 Million | $-92.62K | -0.037x | +95.69% |
| 2018-09-30 | $3.11 Million | $-2.63 Million | -0.847x | -115.74% |
| 2017-09-30 | $7.55 Million | $-2.96 Million | -0.392x | -347.67% |
| 2016-09-30 | $-72.31K | $-11.46K | 0.158x | -86.46% |
| 2015-09-30 | $-11.05K | $-12.93K | 1.170x | +116.68% |
| 2014-09-30 | $5.71K | $-40.01K | -7.013x | -6646.19% |
| 2013-09-30 | $45.74K | $-4.75K | -0.104x | -- |